메뉴 건너뛰기




Volumn 70, Issue 15, 2013, Pages 1342-1346

Comparison of the timing of initial prophylactic palivizumab dosing on hospitalization of neonates for respiratory syncytial virus

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

EID: 84894333192     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120526     Document Type: Article
Times cited : (12)

References (8)
  • 1
    • 77956626066 scopus 로고    scopus 로고
    • Respiratory syncytial virus
    • Kliegman RM, Behrman RE, Jenson HB et al., eds. Philadelphia: Saunders
    • Mcintosh K. Respiratory syncytial virus. In: Kliegman RM, Behrman RE, Jenson HB et al., eds. Nelson textbook of pediatrics, 18th ed. Philadelphia: Saunders; 2007:1388-90.
    • (2007) Nelson Textbook of Pediatrics, 18th Ed. , pp. 1388-1390
    • Mcintosh, K.1
  • 2
    • 0036020209 scopus 로고    scopus 로고
    • Respiratory syncytial virus-coded pediatric hospitalizations, 1997-1999
    • Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997-1999. Pediatr Infect Dis J. 2002; 21:629-32.
    • (2002) Pediatr Infect Dis J , vol.21 , pp. 629-632
    • Leader, S.1    Kohlhase, K.2
  • 3
    • 0031683919 scopus 로고    scopus 로고
    • Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
    • The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998; 102:531-7.
    • (1998) Pediatrics , vol.102 , pp. 531-537
  • 5
    • 16944363559 scopus 로고    scopus 로고
    • Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus
    • Johnson S, Oliver C, Prince GA et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997; 176:1215-24.
    • (1997) J Infect Dis , vol.176 , pp. 1215-1224
    • Johnson, S.1    Oliver, C.2    Prince, G.A.3
  • 6
    • 16644372782 scopus 로고    scopus 로고
    • Palivizumab use in very premature infants in the neonatal intensive care unit
    • Wu SS, Bonaparte J, Pyati S. Palivizumab use in very premature infants in the neonatal intensive care unit. Pediatrics. 2004; 114:e554-6.
    • (2004) Pediatrics , vol.114 , pp. e554-e556
    • Wu, S.S.1    Bonaparte, J.2    Pyati, S.3
  • 7
    • 71949099031 scopus 로고    scopus 로고
    • Policy statement - Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections
    • American Academy of Pediatrics Committee on Infectious Diseases. Policy statement - modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009; 124:1694-701.
    • (2009) Pediatrics , vol.124 , pp. 1694-1701
    • American Academy of Pediatrics Committee on Infectious Diseases1
  • 8
    • 70249101403 scopus 로고    scopus 로고
    • Respiratory syncytial virus prophylaxis in a tertiary care neonatal intensive care unit
    • Katz BZ, Sullivan C. Respiratory syncytial virus prophylaxis in a tertiary care neonatal intensive care unit. Pediatr Infect Dis J. 2009; 28:842-4.
    • (2009) Pediatr Infect Dis J , vol.28 , pp. 842-844
    • Katz, B.Z.1    Sullivan, C.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.